Stock Scorecard



Stock Summary for BridgeBio Pharma Inc (BBIO) - $30.92 as of 3/28/2024 9:05:52 PM EST

Total Score

2 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BBIO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BBIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BBIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for BBIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for BBIO

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 3/20/2024 11:30:00 AM
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BridgeBio Pharma ( NASDAQ:BBIO ) 3/20/2024 11:30:00 AM
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock 3/6/2024 4:53:00 AM
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO ) 3/5/2024 1:00:00 PM
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO ) 3/5/2024 1:00:00 PM
BridgeBio Pharma Announces Proposed Public Offering of Common Stock - BridgeBio Pharma ( NASDAQ:BBIO ) 3/4/2024 9:17:00 PM
BridgeBio Pharma Announces Proposed Public Offering of Common Stock 3/4/2024 9:17:00 PM
What's Going On With BridgeBio Pharma Stock On Monday? - BridgeBio Pharma ( NASDAQ:BBIO ) 3/4/2024 5:31:00 PM
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM 3/4/2024 7:30:00 AM
BridgeBio Pharma ( BBIO ) Reports Q4 Loss, Lags Revenue Estimates 2/22/2024 1:40:00 PM

Financial Details for BBIO

Company Overview

Ticker BBIO
Company Name BridgeBio Pharma Inc
Country USA
Description BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/2/2024

Stock Price History

Last Day Price 30.92
Last Day Price Updated 3/28/2024 9:05:52 PM EST
Last Day Volume 1,995,061
Average Daily Volume 1,877,489
52-Week High 44.32
52-Week Low 12.75
Last Price to 52 Week Low 142.51%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -8.03
Free Cash Flow Ratio 13.10
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 3.32
Total Cash Per Share 2.36
Book Value Per Share Most Recent Quarter -7.74
Price to Book Ratio 123.68
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 611.87
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 184,452,000
Market Capitalization 5,703,255,840
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -33.67%
Reported EPS 12 Trailing Months -3.95
Reported EPS Past Year -3.94
Reported EPS Prior Year -3.11
Net Income Twelve Trailing Months -643,202,000
Net Income Past Year -643,202,000
Net Income Prior Year -481,183,000
Quarterly Revenue Growth YOY -6.70%
5-Year Revenue Growth -26.45%

Balance Sheet

Total Cash Most Recent Quarter 434,884,000
Total Cash Past Year 434,884,000
Total Cash Prior Year 471,922,000
Net Cash Position Most Recent Quarter -1,291,845,000
Net Cash Position Past Year -1,291,845,000
Long Term Debt Past Year 1,726,729,000
Long Term Debt Prior Year 1,707,615,000
Total Debt Most Recent Quarter 1,726,729,000
Equity to Debt Ratio Past Year -3.64
Equity to Debt Ratio Most Recent Quarter -3.64
Total Stockholder Equity Past Year -1,354,257,000
Total Stockholder Equity Prior Year -1,254,617,000
Total Stockholder Equity Most Recent Quarter -1,354,257,000

Options

Put/Call Ratio 0.40
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.06
MACD Signal -1.47
20-Day Bollinger Lower Band 26.13
20-Day Bollinger Middle Band 34.22
20-Day Bollinger Upper Band 42.31
Beta 1.05
RSI 49.30
50-Day SMA 27.26
200-Day SMA 30.52

System

Modified 3/28/2024 6:53:19 PM EST